JP7711959B2 - 改変型アデノウイルスヘキソンタンパク質を有するアデノウイルス - Google Patents

改変型アデノウイルスヘキソンタンパク質を有するアデノウイルス

Info

Publication number
JP7711959B2
JP7711959B2 JP2022523434A JP2022523434A JP7711959B2 JP 7711959 B2 JP7711959 B2 JP 7711959B2 JP 2022523434 A JP2022523434 A JP 2022523434A JP 2022523434 A JP2022523434 A JP 2022523434A JP 7711959 B2 JP7711959 B2 JP 7711959B2
Authority
JP
Japan
Prior art keywords
hadv5
adenovirus
modified
mscs
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552870A5 (cg-RX-API-DMAC7.html
JP2022552870A (ja
Inventor
コハネック、ステファン
クルツケ、リー
シュタイナー、ロビン
ラバース、オリビア
Original Assignee
ウニヴェルズィテート・ウルム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニヴェルズィテート・ウルム filed Critical ウニヴェルズィテート・ウルム
Publication of JP2022552870A publication Critical patent/JP2022552870A/ja
Publication of JP2022552870A5 publication Critical patent/JP2022552870A5/ja
Application granted granted Critical
Publication of JP7711959B2 publication Critical patent/JP7711959B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022523434A 2019-10-21 2020-10-20 改変型アデノウイルスヘキソンタンパク質を有するアデノウイルス Active JP7711959B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19204420.4A EP3812465A1 (en) 2019-10-21 2019-10-21 Adenovirus comprising a modified adenovirus hexon protein
EP19204420.4 2019-10-21
PCT/EP2020/079494 WO2021078735A1 (en) 2019-10-21 2020-10-20 Adenovirus comprising a modified adenovirus hexon protein

Publications (3)

Publication Number Publication Date
JP2022552870A JP2022552870A (ja) 2022-12-20
JP2022552870A5 JP2022552870A5 (cg-RX-API-DMAC7.html) 2023-10-17
JP7711959B2 true JP7711959B2 (ja) 2025-07-23

Family

ID=68296308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523434A Active JP7711959B2 (ja) 2019-10-21 2020-10-20 改変型アデノウイルスヘキソンタンパク質を有するアデノウイルス

Country Status (5)

Country Link
US (1) US12435112B2 (cg-RX-API-DMAC7.html)
EP (3) EP3812465A1 (cg-RX-API-DMAC7.html)
JP (1) JP7711959B2 (cg-RX-API-DMAC7.html)
CA (1) CA3158189A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021078735A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005211A1 (ja) * 2022-06-27 2024-01-04 国立大学法人大阪大学 ヘキソン改変型アデノウイルスベクター

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002525065A (ja) 1998-09-11 2002-08-13 ジェンベク、インコーポレイティッド 選択的にターゲッティングされるアデノウイルス
JP2009535032A (ja) 2006-04-28 2009-10-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 改変アデノウイルスヘキソンタンパク質およびその用途
JP2015506704A (ja) 2012-02-02 2015-03-05 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 腫瘍関連異種抗原を発現するアデノウイルス
JP2016521709A (ja) 2013-06-05 2016-07-25 ベリカム ファーマシューティカルズ, インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
JP2017518765A (ja) 2014-05-14 2017-07-13 ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ アバーディーンThe University Court Of The University Of Aberdeen 膵島細胞入手方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236912C (en) * 1995-11-28 2006-04-25 Genvec, Inc. Vectors and methods for gene transfer to cells
US9017672B2 (en) * 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
ES2899913T3 (es) * 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
EP3247807B1 (en) * 2015-01-20 2020-12-16 Adcure Biotechnologies, LLC. Detargeted adenovirus variants and related methods
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002525065A (ja) 1998-09-11 2002-08-13 ジェンベク、インコーポレイティッド 選択的にターゲッティングされるアデノウイルス
JP2009535032A (ja) 2006-04-28 2009-10-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 改変アデノウイルスヘキソンタンパク質およびその用途
JP2015506704A (ja) 2012-02-02 2015-03-05 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 腫瘍関連異種抗原を発現するアデノウイルス
JP2016521709A (ja) 2013-06-05 2016-07-25 ベリカム ファーマシューティカルズ, インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
JP2017518765A (ja) 2014-05-14 2017-07-13 ザ ユニバーシティー コート オブ ザ ユニバーシティー オブ アバーディーンThe University Court Of The University Of Aberdeen 膵島細胞入手方法

Also Published As

Publication number Publication date
EP4048798A1 (en) 2022-08-31
EP3812465A1 (en) 2021-04-28
WO2021078735A1 (en) 2021-04-29
US12435112B2 (en) 2025-10-07
CA3158189A1 (en) 2021-04-29
EP4407025A3 (en) 2025-01-15
US20220380411A1 (en) 2022-12-01
EP4048798C0 (en) 2024-06-26
JP2022552870A (ja) 2022-12-20
EP4048798B1 (en) 2024-06-26
EP4407025A2 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
JP6375273B2 (ja) 腫瘍選択的e1aおよびe1b変異体
EP2871239B1 (en) Cell capable of producing adeno-associated virus vector
JP3565859B2 (ja) 改良されたアデノウイルスおよびその使用法
KR20220155981A (ko) 미성숙 종결 코돈-매개 장애를 치료하기 위한 방법 및 조성물
JP6388593B2 (ja) E1bタンパク質の156rスプライシングアイソフォームの割合を増加させた腫瘍溶解性アデノウイルス
JP7558808B2 (ja) 組換えアデノウイルスおよびこれを含む幹細胞
CN113227361B (zh) 腺病毒和使用腺病毒的方法
CN111479582B (zh) 免疫调节的复制高效的痘苗病毒株
JP4955397B2 (ja) 腫瘍崩壊性のアデノウイルス
Lundstrom Application of viruses for gene therapy and vaccine development
EP4048798B1 (en) Adenovirus comprising a modified adenovirus hexon protein
JP2004502426A (ja) 平滑筋の発現を制御するキメラプロモーター
JP7508109B2 (ja) ヒト35型アデノウイルスを基盤とした腫瘍溶解性ウイルス
JP7816735B2 (ja) 腫瘍溶解性ウイルス及びそれを用いたがん治療
Thiaville et al. Hope Unlocked: Gene Therapy with Viral Vectors and Gene Editing
JP2010512760A (ja) 組換えkhp53遺伝子のアデノウイルス組換え体及びその調製方法と用途
CN116769734A (zh) 一种缺氧微环境响应溶瘤病毒株的构建及其应用
WO2026003069A1 (en) Constructs and vectors for reprogramming cells to cdc1 cells, compositions and methods thereof
TWI391486B (zh) 新穎啟動子及包含其之病毒載體
HK40057763B (en) Adenoviruses and methods for using adenoviruses
Le Guiner et al. Effective Limb Transduction and Phenotypic Correction after Injection of rAAV8-U7 snRNA in GRMD Dogs
Panakanti Therapeutic gene delivery to human pancreatic islets for treatment of diabetes and the effect of TFO on liver fibrosis induced by bile duct ligation
Kohn et al. Gene therapy and viruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250703

R150 Certificate of patent or registration of utility model

Ref document number: 7711959

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150